These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9354673)

  • 1. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
    Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Jalkanen S
    Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
    Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
    Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
    Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
    Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
    Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
    Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
    Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
    Kollár B; Rajnics P; Hunyady B; Zeleznik E; Jakucs J; Egyed M
    Orv Hetil; 2009 Aug; 150(35):1649-53. PubMed ID: 19692309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
    Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
    Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin's lymphomas: immunologic prognostic studies.
    Hadzi-Pecova L; Petrusevska G; Stojanovic A
    Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
    Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; García-Conde J
    Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Sasaki K; Umeda M
    Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
    Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
    Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.